Genmab — Juli 2017
-
-
Volumen i dag er relativ ringe, så kan vi bruge dagens stigning til noget fornuftigt?
-
Washington Post. Novartis og CAR-T. Rigtig positiv om kræftramt pige, der ser ud til at være blevet rask. 4. afsnit: 'An FDA advisory committee will decide Wednesday whether to recommend approval of the approach, which uses patients’ own genetically altered immune cells to fight blood cancers.' De mange mulige bivirkninger med CAR-T nævnes også
-
•In a unanimous 10 - 0 vote, the FDA's Oncologic Drugs Advisory Committee determines that the benefits of Novartis' (NVS +1.7%) CAR-T therapy tisagenlecleucel-T outweigh the risks in pediatric and young adults with treatment-resistant B-cell acute lymphoblastic leukemia (ALL).
•FDA approval, while not guaranteed, is virtually assured.
-
God morgen. En dejlig patient case at vågne op til, tillykke til Emily. Det er godt nok noget af en estimeret pris for behandlingen, den overrasker mig.
-
God morgen.
-
Jeg mener, at denne fra Myeloma Canada er ny på Clinical Trials: https://clinicaltrials.gov/ct2/show/NCT03215524?term=daratumumab+pomalidomide&draw=1&rank=3
og se at Genmab er kommet strygende op , når man venter at den siver hele sommeren. Man kan heldigvis blive overrasket. Nogen er nok bange for gode nøgletal . 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind